ArticleJournal of nanobiotechnology2026
DSCAML1+ extracellular vesicles revealed by single-vesicle proteomics as a novel biomarker and therapeutic target in myocardial infarction.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicles in heart failure: bridging pathogenic insights, diagnostic utility, and therapeutic applications.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The early and accurate diagnosis of acute myocardial infarction (AMI) remains a significant clinical challenge. To this end, we profiled the surface proteome of individual plasma extracellular vesicles (EVs) from AMI patients using single-vesicle sequencing, aiming to identify disease-associated alterations with diagnostic and therapeutic potential. Profiling the EV surface proteome across healthy controls (HC), coronary artery stenosis (CAS), and AMI revealed 21 differentially expressed proteins (DEPs), 11 of which were uniquely associated with AMI compared to HC. Notably, these included elevated levels of DSCAML1, CR1, ACE2, FN1, CDH15, and C5b‑9. EVs were subsequently stratified into 17 subpopulations, with clusters 1, 8, and 9 characterized by DSCAML1, ALCAM, and CR1, respectively, and showing the highest enrichment in AMI. We further demonstrated that plasma EVs from AMI patients (AMI-EVs) promote cardiomyocyte proliferation and endothelial cell activity in vitro, followed by the finding that the DSCAML1-enriched subpopulation (DSCAML1-EVs) enhances myocardial repair and angiogenesis both in vitro and in vivo, with mechanistic studies implicating the EREG/ERK pathway in these effects. In summary, DSCAML1-positive EVs show dual potential as both a diagnostic biomarker for AMI and a therapeutic target for improving post‑infarction prognosis, providing insight into the translational potential of EV‑based strategies in precision cardiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.